Farther Finance Advisors LLC Grows Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA

Farther Finance Advisors LLC raised its position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 602.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,839 shares of the company’s stock after purchasing an additional 5,866 shares during the period. Farther Finance Advisors LLC’s holdings in Olema Pharmaceuticals were worth $29,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Goldman Sachs Group Inc. raised its position in Olema Pharmaceuticals by 93.6% during the first quarter. Goldman Sachs Group Inc. now owns 741,329 shares of the company’s stock valued at $2,787,000 after purchasing an additional 358,412 shares in the last quarter. Affinity Asset Advisors LLC purchased a new position in shares of Olema Pharmaceuticals in the first quarter worth about $1,222,000. Nuveen LLC purchased a new position in shares of Olema Pharmaceuticals in the first quarter worth about $1,295,000. PDT Partners LLC purchased a new position in shares of Olema Pharmaceuticals in the first quarter worth about $279,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Olema Pharmaceuticals by 23.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 93,979 shares of the company’s stock worth $548,000 after buying an additional 18,005 shares during the period. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Stock Up 2.8%

Shares of NASDAQ:OLMA opened at $10.73 on Thursday. The stock’s 50-day moving average is $7.15 and its 200 day moving average is $5.38. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.09 and a quick ratio of 11.09. The company has a market cap of $736.40 million, a PE ratio of -5.42 and a beta of 2.08. Olema Pharmaceuticals, Inc. has a 1 year low of $2.86 and a 1 year high of $13.51.

Olema Pharmaceuticals (NASDAQ:OLMA) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.08). Sell-side analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on OLMA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Wednesday. JPMorgan Chase & Co. lifted their price objective on Olema Pharmaceuticals from $28.00 to $29.00 and gave the stock an “overweight” rating in a report on Thursday, August 14th. Oppenheimer reiterated an “outperform” rating and issued a $22.00 price objective on shares of Olema Pharmaceuticals in a report on Wednesday, September 3rd. Guggenheim started coverage on Olema Pharmaceuticals in a report on Wednesday. They issued a “buy” rating and a $20.00 price objective on the stock. Finally, Zacks Research upgraded Olema Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 9th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $23.33.

Insiders Place Their Bets

In other Olema Pharmaceuticals news, Director Cyrus Harmon sold 3,086 shares of Olema Pharmaceuticals stock in a transaction that occurred on Thursday, September 18th. The stock was sold at an average price of $8.32, for a total transaction of $25,675.52. Following the sale, the director directly owned 117,028 shares of the company’s stock, valued at approximately $973,672.96. The trade was a 2.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last quarter, insiders sold 25,000 shares of company stock worth $204,841. Insiders own 16.36% of the company’s stock.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.